Otros idiomas Keymed Biosciences Inc.

Acciones

2162

KYG5252B1023

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:06 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
33,95 ^HKD	+1,34 %		+16,47 %	-30,86 %

30/04	La NMPA acepta la NDA para el tratamiento de la alergia de Keymed Biosciences	MT
28/04	Keymed Biosciences Inc. anuncia un ensayo clínico de fase III de Stapokibart inyectable para el tratamiento de la rinitis alérgica estacional	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA	30/04
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points	29/04
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis	28/04
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12/04
KeyMed Biosciences’ Attributable Loss Widens in 2023	27/03
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Keymed Biosciences Buys Back Shares	22/01
Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%	27/12
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps	27/12
China Accepts New Drug Application for Keymed Biosciences' Atopic Dermatitis Injection; Shares Rise 4%	07/12
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection	07/12
Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug	08/11
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901	08/11
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023	11/10/23
Keymed Biosciences’ Profit Surges in H1	25/08/23
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23
Keymed Biosciences to Acquire 18.7% of Kangnuo Xing for 150.6 Million Yuan	27/06/23
Keymed Presents Data on Phase 1 Study for Lymphoma, Myeloma Drug; Shares Fall 4%	12/06/23
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313	12/06/23
Keymed Biosciences Completes Data Unblinding for Phase 3 Study of Eczema Treatment; Shares Rise 8%	30/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Keymed Biosciences Inc.

Acciones

2162

KYG5252B1023

Otros idiomas

Filtros